The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Xalkori

200 milligram(s) Capsule, hard

Pfizer Europe MA EEIGEU/1/12/793/001-002

Main Information

Trade NameXalkori
Active SubstancesCrizotinib
Strength200 milligram(s)
Dosage FormCapsule, hard
Licence HolderPfizer Europe MA EEIG
Licence NumberEU/1/12/793/001-002

Group Information

ATC CodeL01XE16 crizotinib

Status

Authorised/WithdrawnAuthorised
Licence Issued
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
Marketing StatusMarketed

Documents

Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website

Educational Materials - Patient

« Back